Metformin: Unveiling Cancer-Fighting Potential in a Diabetes Drug
Metformin, a widely-used diabetes medication, is gaining attention in the realm of alternative cancer treatments. This drug not only helps regulate blood sugar levels, but also demonstrates promising effects against various cancer types. By targeting molecular pathways such as mTOR, AMPK, IGF-1, and NF-kB, Metformin has shown potential in curbing the growth of breast, prostate, lung, colon, esophageal, and melanoma cancers. However, it is essential to monitor liver health prior to initiating treatment, as Metformin can cause liver inflammation. Additionally, caution is necessary regarding potential contaminants like NDMA, especially in extended-release versions or those sourced from third-world suppliers.
Growing evidence suggests that Metformin could prevent cancer in patients with Type-2 diabetes, who have a higher incidence of cancer due to insulin resistance and mitogenic activity. A 2019 meta-analysis revealed that Metformin could significantly reduce the risk of pancreatic cancer. In a 2021 study involving 44,541 women, those with diabetes who took Metformin for 10 or more years experienced a 38% lower risk of developing ER-positive breast cancer, but faced a higher risk of developing triple-negative breast cancer.
Oncologists have used Metformin off-label to enhance cancer survival since 2005, and since 2012, it has been promoted as one of four drugs in the Care Oncology Protocol. Studies have indicated that patients with Type-2 diabetes who took Metformin had a higher chance of complete remission in breast cancer chemotherapy, a 40% lower progression and death rate in HER2 positive cancer, and increased overall survival in colorectal cancer.
A 2012 Mayo Clinic study discovered that women with ovarian cancer who took Metformin had a 67% survival rate after 5 years, compared to 47% of those who did not take the drug. A 2016 study from the Perelman School of Medicine, Pennsylvania, demonstrated that breast cancer patients who began taking Metformin after their diagnosis were almost 50% more likely to survive. A 2019 meta-study on prostate cancer concluded that there were clear survival benefits from Metformin's multiple actions.
Berberine: The Ultimate Cancer-Fighting Supplement
Berberine, a powerful herb with an extensive range of cancer-fighting properties, has earned our strong endorsement. When taken three times daily at 500mg doses, Berberine has consistently exhibited remarkable benefits in numerous studies.
In several key areas, Berberine outperforms Metformin. Not only does it regulate blood sugar more effectively, but it also rectifies cancer cell mitochondria and elevates AMPK levels. This dual action restores balance to underlying pathways like Akt and mTOR. Furthermore, Berberine possesses antimicrobial and anti-inflammatory properties, which Metformin lacks.
One of Berberine's most notable advantages is its ability to function as a chemosensitizer. This means it can enhance the effectiveness of chemotherapy treatments, unlike Metformin. Regrettably, most oncologists and physicians are more inclined to prescribe drugs rather than herbs or supplements. Consequently, Berberine's immense potential often remains overlooked.
In conclusion, both Metformin and Berberine offer unique benefits in the battle against cancer. While Metformin has proven valuable in various cancer types, Berberine's wide-ranging effects on multiple cancer pathways make it an indispensable addition to any alternative cancer treatment regimen. However, it is crucial to consult with your healthcare provider before incorporating any new treatments into your plan.